(Total Views: 663)
Posted On: 08/01/2020 9:41:42 AM
Post# of 148899
TechGuru,
Are you suggesting they may be trying to "data mine" the 87person cohort into subgroups of mild and moderate? If not, I suppose I am.
This might allow showing a larger response to Leronlimab in the moderate group vs. the mild.
However, a big mystery is not knowing which patients started in the trial as mild might be the ones that progress to moderate and then to severe and so on. For this reason, the quote from NP in the conference call seems most interesting to me "3rd result of another secondary endpoint is in regards to patients who needed oxygen use and mechanical ventilators. Leronlimab arm beats the placebo arm." I am assuming this means noting which patients started as mild/moderate and have progressed to a more serious state. This endpoint seems to me to be a significant proof of efficacy if there are statistically enough patients. (Too bad the study could not be larger).
There is still much be to be learned about COVID. I think the bloodwork and patient condition in this study will be of great value. So, a publication from the investigators involved will be important to the wider medical community. Maybe these bloodwork measurements will help to predict which milds progress to more serious disease? An obvious one might be DPs RANTES levels vs. time correlated to the health of the patient.
Regards,
Are you suggesting they may be trying to "data mine" the 87person cohort into subgroups of mild and moderate? If not, I suppose I am.
This might allow showing a larger response to Leronlimab in the moderate group vs. the mild.
However, a big mystery is not knowing which patients started in the trial as mild might be the ones that progress to moderate and then to severe and so on. For this reason, the quote from NP in the conference call seems most interesting to me "3rd result of another secondary endpoint is in regards to patients who needed oxygen use and mechanical ventilators. Leronlimab arm beats the placebo arm." I am assuming this means noting which patients started as mild/moderate and have progressed to a more serious state. This endpoint seems to me to be a significant proof of efficacy if there are statistically enough patients. (Too bad the study could not be larger).
There is still much be to be learned about COVID. I think the bloodwork and patient condition in this study will be of great value. So, a publication from the investigators involved will be important to the wider medical community. Maybe these bloodwork measurements will help to predict which milds progress to more serious disease? An obvious one might be DPs RANTES levels vs. time correlated to the health of the patient.
Regards,
(0)
(0)Scroll down for more posts ▼
